- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S4002||Sitagliptin phosphate monohydrate||41 mg/mL||100 mg/mL||<1 mg/mL|
|S3031||Linagliptin||<1 mg/mL||17 mg/mL||1 mg/mL|
|S3033||Vildagliptin (LAF-237)||60 mg/mL||60 mg/mL||60 mg/mL|
|S1540||Saxagliptin||63 mg/mL||63 mg/mL||24 mg/mL|
|S2868||Alogliptin（SYR-322）benzoate||2 mg/mL||68 mg/mL||<1 mg/mL|
|S5365||Alogliptin||18 mg/mL||67 mg/mL||67 mg/mL|
|S5079||Sitagliptin||-1 mg/mL||81 mg/mL||-1 mg/mL|
|S5063||Trelagliptin succinate||95 mg/mL||95 mg/mL||5 mg/mL|
|S8565||Omarigliptin (MK-3102)||<1 mg/mL||79 mg/mL||<1 mg/mL|
|S7513||Trelagliptin||<1 mg/mL||71 mg/mL||3 mg/mL|
|S4697||Saxagliptin hydrate||1 mg/mL||66 mg/mL||66 mg/mL|
|S4636||Teneligliptin hydrobromide||100 mg/mL||100 mg/mL||17 mg/mL|
- DPP-4 Inhibitors (12)
- New DPP-4 Products
|Catalog No.||Information||Product Use Citations||Product Validations|
Sitagliptin phosphate monohydrate is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.
AR staining of non-CAVD and CAVD patient hVICs in the presence or absence of Sitagliptin (100 μM) after 4 weeks of osteogenic stimulation. The bar graph presents the AR-positive area measured in each culture dish.
Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP-9.
Vildagliptin (LAF-237) inhibits DPP−4 with IC50 of 2.3 nM.
Saxagliptin is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4)with IC50 values of 2.63 nM and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9.
Sitagliptin is an oral and highly selective DPP-4 inhibitor with an IC50 of 18 nM. It is used for the treatment of type 2 diabetes.
Trelagliptin succinate is a dipeptidyl peptidase IV (DPP-4) inhibitor which is used as a new long-acting drug for once-weekly treatment of type 2 diabetes mellitus (DM).
Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).
Trelagliptin is a highly selective, long-acting DPP-4 inhibitor. Phase 3.
Saxagliptin H2O is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.